CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010
Revenue:
Product	$ 31,732	$ 26,915	$ 88,049	$ 71,734
Funded research and development	466	329	982	888
Total Revenue	32,198	27,244	89,031	72,622
Costs and expenses:
Cost of product revenue excluding amortization of intangibles	6,279	5,437	17,721	16,129
Research and development	6,140	6,592	19,923	19,834
Selling, general and administrative	17,184	15,592	51,683	45,399
Amortization of intangible assets	362	295	1,126	1,034
Costs and Expenses, Total	29,965	27,916	90,453	82,396
Income (loss) from operations	2,233	(672)	(1,422)	(9,774)
Other income and expense:
Investment expense, net	(2)	4	(4)	1
Gain on sale of WorldHeart stock				456
Gain on settlement of investment	1,017		1,017
Other income (expense), net	39	30	24	(17)
Nonoperating Income (Expense), Total	1,054	34	1,037	440
Income (loss) before provision for income taxes	3,287	(638)	(385)	(9,334)
Provision for income taxes	366	164	687	649
Net income (loss)	$ 2,921	$ (802)	$ (1,072)	$ (9,983)
Basic net income (loss) per share	$ 0.08	$ (0.02)	$ (0.03)	$ (0.27)
Basic weighted average shares outstanding	38,498	37,195	38,221	37,146
Diluted net income (loss) per share	$ 0.07	$ (0.02)	$ (0.03)	$ (0.27)
Diluted weighted average shares outstanding	40,270	37,195	38,221	37,146